TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03415425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Version of the Influenza Alert
Description: Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Modifications of the Influenza Alert
Description: Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
Study: NCT01166789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 48ug daily taken as 24ug capsules twice per day, in morning and evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily, taken in morning and evening
Study: NCT02725450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery + Psychomotor Battery of fine motor skills
Description: Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Battery of fine motor skills Practice
Description: Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
Study: NCT01481350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
Study: NCT04981106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise
Description: The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared.
Study: NCT02110849

Intervention type: RADIATION
Intervention: Proton
Description: Proton Therapy for Prostate Cancer
Study: NCT02351739

Intervention type: DRUG
Group type: OTHER
Intervention: pembrolizumab

Intervention type: DRUG
Group type: OTHER
Intervention: ACP-196 in combination with pembrolizumab
Study: NCT00609804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily by mouth
Study: NCT04449276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV Vaccine
Description: Participants will receive an intramuscular injection by needle in the deltoid area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intramuscular injection by needle in the deltoid area.
Study: NCT03263741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + S-1 + Oxaliplatin
Description: Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
Study: NCT04055467

Intervention type: DRUG
Group type: OTHER
Intervention: [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
Description: Brain imaging of alpha-7 nicotinic acetylcholine receptors

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
Study: NCT02040155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel nano-scintillator fiber-optic dosimeter (nanoFOD)
Description: This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
Study: NCT03023241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
Study: NCT04126603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo injection
Study: NCT04029623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partnered Rhythmic Rehabilitation (PRR)
Description: Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
Study: NCT02673099

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HDF online
Description: Hemodialysis by the HDF online method
Study: NCT03279887

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Study: NCT03570242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study: NCT05290506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
Study: NCT04029623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group walking (WALK)
Description: WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
Study: NCT02560480

Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: to diagonose groin injury exactly in magnetic resonance imaging

Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: to diagonose groin injury exactly in magnetic resonance imaging
Study: NCT02061748

Intervention type: DRUG
Intervention: Observational
Description: Retrospective Chart Review
Study: NCT04488081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Study: NCT02989714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
Study: NCT03035370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin PT 25 mcg
Description: Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
Study: NCT04488081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Study: NCT03035370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin PT 50 mcg
Description: Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin PT Placebo
Description: Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
Study: NCT05290506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
Study: NCT01848067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT04482972

Intervention type: PROCEDURE
Intervention: DCB
Description: Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.

Intervention type: PROCEDURE
Intervention: DES
Description: Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
Study: NCT03398941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
Description: Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
Study: NCT01527240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosprin A
Description: The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Saline Solution.
Description: Saline Solution is administered once 15 min after thrombolysis.
Study: NCT01865318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT02680938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
Study: NCT00521209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Stimulating Disease Prevention Program (SCSDPP)
Description: The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Stand procedures, no intervention
Study: NCT02051751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
Study: NCT01963793

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: Aprepitant gel (10 mg/g)

Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: Aprepitant gel (10 mg/g)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: gel without active component

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: gel without active component
Study: NCT03813758

Intervention type: DIAGNOSTIC_TEST
Intervention: wrinkle test
Description: soaking in 40 deg water for 40 min. every 10 min the hand will be photo

Intervention type: DIAGNOSTIC_TEST
Intervention: wrinkle test
Description: soaking in 40 deg water for 40 min. every 10 min the hand will be photo
Study: NCT03376711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Peer Support Program
Description: The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs.
Study: NCT02544035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Toy
Description: Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Toy
Description: Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Toy
Description: Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Toy
Description: Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Partner
Description: Each child will first play alone then play with parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Partner
Description: Each child will first play alone then play with parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Partner
Description: Each child will first play alone then play with parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Partner
Description: Each child will first play alone then play with parent.
Study: NCT01059045

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: cryocontact therapy
Description: cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryocontact therapy
Description: cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: No intervention